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Polymorphic conversionIn this study solid dispersions of carbamazepine in the hydrophilic Kollidon VA64 polymer, adsorbed
onto Neusilin UFL2 adsorption carrier have been employed to improve carbamazepine dissolution rate.
In order to evaluate effects of changing in the proportions of all solid dispersion components on carba-
mazepine dissolution rate, D-optimal mixture experimental design was used in the formulation develop-
ment. From all prepared solid dispersion formulations, significantly faster carbamazepine dissolution was
observed compared to pure drug. Ternary solid dispersions containing carbamazepine, Kollidon VA64
and Neusilin UFL2 showed superior dissolution performances over binary ones, containing only carba-
mazepine and Neusilin UFL2. Proportion of Kollidon VA64 showed the most profound effect on the
amount of carbamazepine dissolved after 10 and 30 min, whereby these parameters increase upon
increasing in Kollidon VA64 concentrations up to the middle values in the studied range of Kollidon
VA64 concentrations. Physicochemical characterization of the selected samples using differential scan-
ning calorimetry, FT-IR spectroscopy, powder X-ray diffraction and polarizing light microscopy showed
polymorphic transition of carbamazepine from more thermodynamically stable monoclinic form (form
III) to less thermodynamically stable triclinic form (form I) in the case of ternary, but not of binary solid
dispersion formulations. This polymorphic transition can be one of the factors responsible for improving
of carbamazepine dissolution rate from studied solid dispersions. Ternary solid dispersions prepared with
Kollidon VA64 hydrophilic polymer and Neusilin UFL2 adsorption carrier resulted in significantly
improvement of carbamazepine dissolution rate, but formation of metastable polymorphic form of car-
bamazepine requires particular care to be taken in ensuring product long term stability.
 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Increase using of combinatorial chemistry and high throughput
screening in the development of new drugs led to development of
huge number of compounds with good pharmacological activity,
but unfortunately very low aqueous solubility. Since drugdissolution is prerequisite for its absorption, low drug solubility
and dissolution rate will limit drug bioavailability after oral admin-
istration. Numerous approaches have been applied for improving
drugs dissolution rate and bioavailability, including formation of
prodrugs (Rautio et al., 2008) and salts (Serajuddin, 2007), particle
size reduction (Leleux and Williams, 2014), complexation with
cyclodextrins (Loftsson et al., 2005), formulation of solid disper-
sions (Vo et al., 2013), nanocrystalline systems (Möschwitzer,
2013) and lipid-based drug delivery systems (Feeney et al.,
2016). Although application of solid dispersions was in a lot of
cases accompanied with improved drug solubility and oral
bioavailability, wider commercial application of this approach is
very limited due to problems in ensuring long term product
stability as a consequence of polymorphic transitions and
crystalline-amorphous transitions and difficult further processing
of solid dispersions into final dosage form as a result of their sticky
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(Serajuddin, 1999; Vo et al., 2013). It has been shown that adsorp-
tion of solid dispersions onto inert carriers with high specific sur-
face area is very effective strategy to enable further processing of
these systems into final dosage form, with maintaining fast drug
release (Gupta et al., 2001, Gupta et al., 2002). Higher drug disso-
lution rate from these ternary systems is not only consequence
of intricate properties of solid dispersions, such as generation of
amorphous form of API, improved wetting and decrease in particle
size, but also of increased surface area due to using of adsorption
carrier (Gupta et al., 2001). In addition, adsorption carrier can fur-
ther stabilize drug within the solid dispersion matrix, due to speci-
fic chemical interactions, as well as prevention of crystal growth
due to very confined space inside the carrier pores (Censi et al.,
2016). Neusilin is an amorphous, synthetic form of magnesium
aluminometasilicate, available in different grades and is commonly
used for pharmaceutical applications as a carrier and filler for
improving the quality of tablets, powders, granules and capsules
(Censi et al., 2016). Particular success with using of this carrier
has been achieved in solidification of self-emulsifying drug deliv-
ery systems (Milovic´ et al., 2012; Qi et al., 2014; Williams et al.,
2014) as well as solid dispersions (Gupta et al., 2001, 2002).
Carbamazepine (CBZ) is an antiepileptic drug with poor aque-
ous solubility which is responsible for its low and irregular oral
bioavailability (Sethia and Squillante, 2002). Since CBZ exhibits
dissolution-limited bioavailability, numerous approaches have
been applied to improve its dissolution rate, including micronisa-
tion (Bolten and Türk, 2012), nanocrystallization (Wang et al.,
2012), co-crystallization (Chieng et al., 2009; Yamamoto et al.,
2012), formulation of binary and ternary solid dispersions
(Medarevic et al., 2016a,b; Djuris et al., 2014; Martins et al.,
2012) self-emulsifying drug delivery systems (Milovic´ et al.,
2012), complexation with cyclodextrins (Jain et al., 2011;
Medarevic et al., 2015) and adsorption onto mesoporous silicates
(Ambrogi et al., 2008; Van Speybroeck et al., 2009). CBZ is known
to exhibit polymorphism, with at least four known anhydrous
polymorphic forms, as well as numerous solvates (Kipouros et al.,
2006). Since it has been demonstrated that in some of the formu-
lation approaches for improving CBZ dissolution rate, polymorphic
transitions occur (Otsuka et al., 1997; Murphy et al., 2002), partic-
ular attention should be paid to the comprehensive solid state
characterization methods, in order to timely detect these transi-
tions. In this study, ternary solid dispersions containing CBZ and
Kollidon VA 64 (vinyl pyrrolidone/vinyl acetate copolymer at a
ratio of 6:4), adsorbed onto Neusilin UFL2 carrier have been
developed to improve dissolution rate of CBZ. Neusilin UFL2
was included in the formulation due to numerous benefits in solid
dispersions formulation, such as increasing of surface area, better
dispersing of solid dispersion powder in an aqueous medium,
due to lower tendency towards agglomeration, and also facilitation
of solid dispersion production process which enables production of
powder suitable for further processing into final dosage form. D-
optimal mixture experimental design was applied in order to find
optimal composition of solid dispersion, which provides the fastest
CBZ dissolution. Comprehensive physicochemical characterization
was performed in order to evaluate changes in CBZ physical state
in the prepared solid dispersions, as well as presence of interac-
tions between CBZ and other solid dispersion components.2. Materials and methods
2.1. Materials
Neusilin UFL2 (magnesium aluminometasilicate) (Fuji Chemi-
cal Industry, Japan) and water soluble copolymer Kollidon VA64(vinyl pyrrolidone/vinyl acetate copolymer at a ratio of 6:4) (BASF,
Ludwigshafen, Germany), both kindly donated by the manufactur-
ers, were used as components of solid dispersion matrix. Absolute
ethanol (Merck, Darmstadt, Germany) was used as a solvent for
solid dispersions preparation. CBZ (Ph. Eur. 9.0), kindly donated
by Galenika AD (Belgrade, Serbia), was used as a model of poorly
soluble drug.
2.2. Methods
2.2.1. Experimental design and analysis
D-optimal mixture experimental design was used to evaluate
the influence of solid dispersion composition on CBZ dissolution
rate. The limits for the solid dispersion components proportions
were in the following range: 20%  A  50%, 30%  B  80%, 0% 
C  20%, where A, B and C are proportions of CBZ, Neusilin UFL2
and Kollidon VA64, respectively. D-optimal mixture experimental
design was used because setting of the constraints for components
proportions in the previous way gave irregularly shaped experi-
mental space, so using of asymmetric types of experimental design
is strongly recommended (Dejaegher and Heyden (2011)). Design
expert software 7.0.0 (Stat-Ease, Inc., Minneapolis, MN, USA) was
used for the development of the D-optimal mixture experimental
design matrix that had a total of 20 experimental runs (Table 1).
Independent variables were proportions of CBZ, Neusilin UFL2
and Kollidon VA64, while the responses (Y1 and Y2) were the
amounts of dissolved CBZ (%) from solid dispersions after 10
(Q10) and 30 (Q30) minutes.
Obtained data were fit into the linear (Eq. (1)), quadratic
(Eq. (2)), special cubic (Eq. (3)) and cubic (Eq. (4)) Scheffe’s models:
Y ¼ b1Aþ b2Bþ b3C ð1Þ
Y ¼ b1Aþ b2Bþ b3Cþ b12ABþ b13ACþ b23BC ð2Þ
Y ¼ b1Aþ b2Bþ b3Cþ b12ABþ b13ACþ b23BCþ b123ABC ð3Þ
Y ¼ b1Aþ b2Bþ b3Cþ b12ABþ b13ACþ b23BCþ b123ABC
þ c12ABðA BÞ þ c13ACðA CÞ þ c23BCðB CÞ ð4Þ
where b1–b123, c13–c23 are coefficients of the mathematical model.
Analysis of variance (ANOVA) test was used to assess statistical
significance of the factor effects, where effects with p < 0.05 were
considered as statistical significant. Obtained polynomial models
were visualized as contour and trace plots.
2.2.2. Solid dispersions preparation
Solid dispersions were prepared according to previously defined
experimental plan (Table 1). Neusilin UFL2 was dispersed in
ethanolic solution of CBZ and Kollidon VA64 under stirring on a
magnetic stirrer (RCT basic, IKA Labortechnik, Staufen, Germany).
Evaporation of ethanol from the prepared dispersions was per-
formed using rotary vacuum evaporator (Büchi Rotavapor, Büchi
Labortechnik AG, Flawil, Switzerland) at a temperature of 70 C.
After evaporation, precipitated material was scrapped off and
stored for 48 h in a desiccator. Samples were further pulverized
in a mortar with a pestle and afterwards sieved through 300 mm
sieve. Until further analysis, samples were kept in sealed glass
vials, away from light and moisture.
2.2.3. Dissolution testing
CBZ dissolution rate from the samples of pure drug and pre-
pared solid dispersions was tested using rotating paddle apparatus
(Erweka DT70, Erweka, Germany). Distilled water (900 ml) was
used as a dissolution medium, since CBZ exhibits pH-
independent solubility (Keramatnia et. al., 2015), while test was
Table 1
The composition of the prepared solid dispersions with the obtained values of the dependent variables according to D-optimal mixture experimental design matrix.
Mixture components (%) Responses
CBZ (%) Neusilin UFL2 (%) Kollidon VA64 (%) Q10 (%) Q30 (%)
F1 50.00 39.47 10.53 48.38 63.45
F2 42.99 57.01 0.00 18.65 34.94
F3 50.00 39.47 10.53 48.08 61.80
F4* 26.15 68.82 5.04 46.61 57.76
F5 20.00 80.00 0.00 17.03 28.29
F6 34.53 45.52 19.94 31.10 46.18
F7 20.00 80.00 0.00 16.20 26.51
F8* 27.15 54.54 18.32 43.91 52.45
F9 20.00 63.59 16.41 43.61 53.69
F10 34.72 58.21 7.07 42.07 52.00
F11 41.61 48.30 10.09 47.52 59.02
F12 47.26 32.74 20.00 36.99 49.15
F13 20.00 63.59 16.41 43.36 52.56
F14* 47.26 32.74 20.00 36.79 50.57
F15* 44.33 39.79 15.87 54.89 73.25
F16* 34.94 51.99 13.07 36.74 47.35
F17 22.61 66.19 11.20 39.20 45.54
F18 20.00 60.00 20.00 42.51 55.64
F19 42.57 52.44 4.99 54.77 68.09
F20 33.86 62.73 3.41 39.55 50.77
* Replicated experiments.
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dispersion samples equivalent to single therapeutic dose of CBZ of
200 mg was used in the testing. 4 ml aliquots were taken at prede-
termined intervals (5, 10, 15, 20 and 30 min), followed by replace-
ment with the same volume of fresh medium. Withdrawn aliquots
were filtered through a membrane filter (0.45 lm) and amount of
dissolved CBZ was determined by UV spectrophotometry at a
wavelength of 287 nm using Evolution 300 UV–Vis spectropho-
tometer (Thermo Fisher Scientific, Waltham, MA). Results are pre-
sented as mean values of three replicates ± standard deviation.
2.2.4. Physicochemical characterization of solid dispersion samples
Based on the results of dissolution testing, formulations F5 (20%
CBZ, 80% Neusilin UFL2), F12 (47.26% CBZ, 32.74% Neusilin UFL2,
20% Kollidon VA64) and F15 (44.33% CBZ, 39.79% Neusilin UFL2,
15.87% Kollidon VA64) were selected as representative for physic-
ochemical characterization. Formulations for physicochemical
characterization were chosen based on the observed differences
in drug dissolution profiles in order to elucidate possible mecha-
nisms responsible for improvement of CBZ dissolution rate.
2.2.4.1. Differential scanning calorimetry (DSC). DSC analyses were
performed on a DSC 204 F1 Phoenix differential scanning calorime-
ter (NETZSCH, Germany). Accurately weighted 5–10 mg of samples
were placed in pierced aluminium pans, and subjected to heating
at 10 C/min in the range of 25–220 C under nitrogen purge gas
flow of 70 ml/min. An empty pan was used as a reference.
2.2.4.2. Fourier transform infrared spectroscopy (FT-IR). FT-IR spectra
were recorded using Nicolet iS10 (Thermo Scientific, Waltham, MA,
USA) FT-IR spectrometer equipped with a single reflection ATR sys-
tem (Smart iTR, Thermo Scientific, Waltham, MA, USA) with dia-
mond plate and ZnSe lens. The spectra were collected in the
frequency range from 4000 to 650 cm1, with the resolution of 4
cm1, as an average of 16 scans.
2.2.4.3. Powder X-ray diffraction analysis (PXRD). PXRD patterns in
transmission mode were recorded using Bruker D8 advance
diffractometer equipped with focusing Ge-crystal primary
monochromator (Johanson type) that generates CuKa1 radiation
(k = 1. 541 Å), within 4–45 2h range in steps of 0.05 and scanning
time of 12 s per step.2.2.4.4. Polarizing light microscopy. Selected samples of solid disper-
sions were dispersed in a silicone oil and observed by polarizing
microscope (Olympus BX53P, Olympus, Japan) under cross polars.
Photos were acquired using cellSens Entry Version 1.14 software
(Olympus, Japan).3. Results and discussion
3.1. CBZ dissolution from solid dispersions
Dissolution profiles of CBZ from the samples of pure drug and
prepared formulations are shown on Fig. 1. From the presented dis-
solution profiles, it can be observed that pure CBZ dissolves slowly
and incompletely, with less than 30% of dissolved drug after 30
min of testing. Dissolution of CBZ from all prepared dispersions
was faster relative to pure CBZ. The fastest CBZ dissolution rate
was achieved from the formulation F15 (44.33% CBZ, 39.79% Neu-
silin UFL2, 15.87% Kollidon VA64), with 73.25% of dissolved CBZ
after 30 min of testing. While about 15% of pure CBZ was dissolved
from the samples of pure drug within the first 10 min, more than
40% of CBZ was dissolved from 11 of 20 of the prepared solid dis-
persion formulations during the same time period. The slowest CBZ
dissolution was observed from the formulations of binary solid dis-
persions F2 (42.99% CBZ, 57.01% Neusilin UFL2), F5 (20% CBZ, 80%
Neusilin UFL2) and F7 (20% CBZ, 80% Neusilin UFL2) that contain
only CBZ adsorbed onto Neusilin UFL2. This clearly shows that
addition of Kollidon VA64 is required to provide desired improve-
ment of CBZ dissolution rate.
Mixture experimental design was applied to further analyse the
impact of proportions of CBZ, adsorption carrier and polymer on
the dissolution rate of CBZ. The models depicting the effects of
the mixture components proportions on the amount of CBZ
released after 10 (Q10) and 30 (Q30) minutes are shown in L-
pseudo scale in Eqs. (5) and (6):
Q10 ¼ 37:28Aþ 17:84B 193:58Cþ 381:54ACþ 433:17BC ð5ÞQ30 ¼ 61:35Aþ 28:09B 135Cþ 287:33ACþ 357:64BC ð6Þ
In order to facilitate the understanding of factor effects, the
results are shown as contour, trace and two component mix graphs
(Fig. 2a–f). From the contour plots, it can be observed that the low-
est CBZ dissolution rate is characteristic for formulations that con-
Fig. 1. Dissolution profiles of CBZ from the samples of pure drug and prepared solid dispersions.
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blue). On the other hand, the fastest CBZ dissolution was observed
when CBZ proportion is on the upper limit of the studied range
(50%), with presence of 10–15% of Kollidon VA64 (yellow and
orange areas on the plot). Trace plots show the effect of changing
in the proportions of individual components on the response val-
ues. These plots (Fig. 2b and e) show the most pronounced effect
of changing in the proportion of Kollidon VA64, where the
amount of dissolved CBZ increases up to some optimal concentra-
tion of Kollidon VA64, than reach plateau and start to decrease.
From the two component mix graphs (Fig. 2c and f) it can be
observed that optimal ratio of CBZ:Kollidon VA64 that provides
the fastest CBZ dissolution from the evaluated ternary solid disper-
sions is 3–3.5:1. From the presented trace plots, it seems that Neu-
silin UFL2 negatively affect CBZ dissolution rate, i.e. amount of
dissolved CBZ decreases with increasing proportion of this adsorp-
tion carrier. However, this effect can be rather attributed to highly
pronounced increase of CBZ dissolution rate with increase in both
proportions of CBZ and Kollidon VA64 and the slowest CBZ disso-
lution rate from the formulations that contain high amount of Neu-
silin UFL2, but not Kollidon VA64.
3.2. Differential scanning calorimetry (DSC)
DSC thermogram of CBZ (Fig. 3a) showed two characteristic
endothermic peaks separated by one exothermic peak. First
endothermic peak at 178 C corresponds to melting of CBZ poly-
morphic form III, which confirmed that CBZ raw material contains
this polymorphic form, which is the only one acceptable by the
European Pharmacopoeia. Following exothermic peak at 180 C is
attributed to recrystalization of polymorphic form I from the melt.
Recrystallized form I further melts at 195 C, giving sharp
endothermic peak (Grzesiak et al., 2003). Broad endotherms on
the DSC curves of Neusilin UFL2 and Kollidon VA64 (Fig. 2b) cor-
respond to loss of absorbed and adsorbed water, as well as glasstransition of these amorphous materials. Presence of endothermic
peaks in the thermograms of all analysed solid dispersion samples
(Fig. 3c) indicates on presence of CBZ in the crystalline state. First
endothermic peak exhibits broad shape due to progressive melting
of some amount of CBZ upon heating, or CBZ dissolution within the
Kollidon VA64 due to progressive heating. Second endothermic
peak, present on the thermograms of formulations F5 (194 C)
and F12 (192.5 C), indicates the presence of some amount of poly-
morphic form I in the samples that can be present initially, or form
during heating in the DSC analysis, like in the case of pure CBZ
(Fig. 3a). Although this peak was not present on the thermogram
of sample F15 (44.33% CBZ, 39.79% Neusilin UFL2, 15.87% Kolli-
don VA64), presence of CBZ polymorphic form I in this sample
cannot be excluded due to possible dissolution of the considerable
amount of CBZ within the Kollidon VA64 upon progressive heat-
ing applied in the DSC procedure. Additionally, in the case of sam-
ple F5 (20% CBZ, 80% Neusilin UFL2), where the second peak was
the most pronounced, there is no Kollidon VA64 present, which
can dissolve some CBZ crystals during heating or prevent recrys-
tallisation of polymorphic form I via intermolecular interactions.
The results of DSC analysis proved that CBZ was present in the
crystalline form in all analysed solid dispersion samples. Since
the changes of polymorphic form of CBZ due to heating during
DSC analysis are possible, DSC is not reliable technique to identify
CBZ polymorphic form present in the sample. Therefore, identifica-
tion of polymorphic form of CBZ was performed using PXRD tech-
nique under ambient temperature.
3.3. Powder X-ray diffraction analysis (PXRD)
Diffractograms of raw materials and prepared formulations,
obtained by PXRD analysis are presented on Fig. 4. PXRD pattern
of pure CBZ showed characteristic peaks at 13.15, 14.25, 15.36,
15.9, 19.55, 23.45, 25.0 and 27.7 2h, which corresponds to pre-
viously reported PXRD pattern of polymorphic form III of CBZ
Fig. 2. (a) Contour plot, (b) trace plot and (c) two component mix graph illustrating the effects of CBZ (A), Neusilin UFL2 (B) and Kollidon VA64 (C) proportions on Q10. (d)
Contour plot, (e) trace plot and (f) two component mix graph illustrating the effects of component proportions on Q30. The reference blend on trace plots was set as follows:
CBZ (A) 35%, Neusilin UFL2 (B) 55% and Kollidon VA64 (C) 10%. Proportion of Neusilin UFL2 (B) on two component mix graphs was set on 55%
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and Kollidon VA64 exhibit diffusive broad pattern, without any
diffraction peaks, due to amorphous nature of these excipients.
Diffractograms of all three analysed formulations showed diffrac-
tion peaks indicating crystalline or partially crystalline nature of
CBZ within these solid dispersion samples. On the diffractogramof formulation F5, containing CBZ at the lowest level in the study
(20%) and Neusilin UFL2 (80%), without Kollidon VA64, most of
CBZ diffraction peaks disappeared, while remaining peaks showed
considerable reduction of intensity. This indicates that CBZ in this
formulation partially transformed into amorphous form. Position
of three distinguishable peaks on the diffractogram of this formu-
Fig. 3. DSC thermograms of raw materials and selected samples of solid dispersions
(F5 - 20% CBZ, 80% Neusilin UFL2; F12 - 47.26% CBZ, 32.74% Neusilin UFL2, 20%
Kollidon VA64; F15 - 44.33% CBZ, 39.79% Neusilin UFL2, 15.87% Kollidon VA64).
Fig. 4. PXRD patterns of raw materials and selected samples of solid dispersions (F5
- 20% CBZ, 80% Neusilin UFL2; F12 - 47.26% CBZ, 32.74% Neusilin UFL2, 20%
Kollidon VA64; F15 - 44.33% CBZ, 39.79% Neusilin UFL2, 15.87% Kollidon VA64).
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diffractogram of polymorphic form III, indicating absence of poly-
morphic transitions during preparation of this sample. However,CBZ peaks showed significant shifting in the diffractograms of for-
mulations F12 (47.26% CBZ, 32.74% Neusilin UFL2, 20% Kollidon
VA64) and F15 (44.33% CBZ, 39.79% Neusilin UFL2, 15.87% Kolli-
don VA64), with appearance of two new peaks, positioned at
5.05 and 8.8 2h. Observed PXRD changes proved that some
amount of CBZ transformed from starting monoclinic form III to
triclinic form I, as previously reported by Martins et al. (2012) for
similar ternary solid dispersion system prepared with CBZ, Gelu-
cire 50/13 and colloidal silicone dioxide. Based on the results of
PXRD analysis, it can be concluded that during preparation of tern-
ary solid dispersions with CBZ, Neusilin UFL2 and Kollidon VA64,
polymorphic transition from polymorphic form III into polymor-
phic form I occurred. Although the results of PXRD analysis is not
in agreement with the results of DSC, definitive conclusion regard-
ing polymorphic form of CBZ present in the sample was drawn
from the results of PXRD, due to absence of heating in this tech-
nique, which can induce undesired polymorphic transition.
3.4. Polarizing light microscopy
Distinct crystal morphology between CBZ polymorphs allows
using of polarizing microscopy for identification of possible poly-
morphic transitions (Rustichelli et al., 2000). Appearance of needle
shaped crystals in the micrographs of formulations F12 (47.26%
CBZ, 32.74% Neusilin UFL2, 20% Kollidon VA64) and F15
(44.33% CBZ, 39.79% Neusilin UFL2, 15.87% Kollidon VA64)
(Fig. 5b and c) indicated that CBZ changed polymorphic form from
monoclinic form III (prismatic shaped) to triclinic form I (needle
shaped). However, needle shaped crystals were not observed on
the photomicrographs of formulation F5 (20% CBZ, 80% Neusilin
UFL2) (Fig. 5a), indicating that there was not polymorphic conver-
sion from form III to form I. Characteristic particle shape of CBZ
polymorphs I and III, observed under polarizing microscope, agree
with PXRD pattern of all three analysed formulations. Visual obser-
vation also confirmed that using of DSC for identification of CBZ
polymorphic transition in the case of these formulations gives mis-
leading conclusions.
3.5. Fourier transform infrared spectroscopy (FT-IR)
FT-IR spectroscopy was used to detect presence of possible
interactions between CBZ, Kollidon VA64 and Neusilin UFL2,
that, if present, should result in shifting of the absorption bands
Fig. 5. Photomicrographs of formulations (a) F5 (20% CBZ, 80% Neusilin UFL2), (b)
F12 (47.26% CBZ, 32.74% Neusilin UFL2, 20% Kollidon VA64) and (c) F15 (44.33%
CBZ, 39.79% Neusilin UFL2, 15.87% Kollidon VA64) obtained by samples analyzing
by polarizing microscope under cross polars.
Fig. 6. FT-IR spectra of rawmaterials and selected samples of solid dispersions (F5 -
20% CBZ, 80% Neusilin UFL2; F12 - 47.26% CBZ, 32.74% Neusilin UFL2, 20%
Kollidon VA64; F15 - 44.33% CBZ, 39.79% Neusilin UFL2, 15.87% Kollidon VA64).
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tion. FT-IR spectra of raw materials and prepared solid dispersion
formulations are shown on Fig. 6. FT-IR spectra of CBZ showed
characteristic absorption bands at 3463 cm1 (ANH valence vibra-
tion), 1674 cm1 (ACOAR vibration), 1593 cm1 and 1605 cm1
(range of AC@CA and AC@O vibration and ANH deformation),
which is in line with the spectra previously reported in the litera-
ture (Rustichelli et al., 2000; Grzesiak et al., 2003). Considerable
shifting of the major absorption bands of CBZ has been observed
on the spectra of all three analysed formulations. On the spectrum
of formulation F5 (20% CBZ, 80% Neusilin UFL2), sharp absorption
peak of CBZ, positioned at 3463 cm1, changed to broad absorptionband positioned around 3460 cm1, while absorption band posi-
tioned at 1674 cm1 shifted to 1652 cm1. Other absorption bands
of CBZ became indistinguishable. Formulations F12 (47.26% CBZ,
32.74% Neusilin UFL2, 20% Kollidon VA64) and F15 (44.33%
CBZ, 39.79% Neusilin UFL2, 15.87% Kollidon VA64) showed very
similar IR spectra. These spectra are characterised with broad
absorption band, with small peak at 3481 cm1 and sharp absorp-
tion bands at 1682, 1733, 1591 and 1603 cm1. It is obvious that
CBZ peaks positioned at 3463 cm1 (ANH valence vibration) and
1674 cm1 (ACOAR vibration) on the spectra of raw material
exhibited the highest extent of changes, indicating significant
intermolecular interactions, possible hydrogen bonding, between
amide group of CBZ and carbonyl group of Kollidon VA64 and/
or silanol group of Neusilin UFL2.
The results of physicochemical characterisation of the selected
samples of solid dispersions showed polymorphic transition of
CBZ from more thermodynamically stable monoclinic form (form
III) to less thermodynamically stable triclinic form (form I) in the
case of ternary solid dispersion formulations. It has been previ-
ously shown by Kobayashi et al. (2000) that form I exhibits faster
initial dissolution rate, which is further diminished by its rapid
conversion to dihydrate form. Therefore, formation of metastable
polymorph is also one of the factors that contribute to improve
CBZ dissolution rate from tested ternary solid dispersions, in addi-
tion to improved wetting, high specific surface area of adsorption
carrier, reduce CBZ particle size and reduce particle agglomeration.
732 T. Vojinovic´ et al. / Saudi Pharmaceutical Journal 26 (2018) 725–7324. Conclusion
In the present study, formulation of ternary solid dispersions
with Neusilin UFL2 as a high specific surface area adsorption car-
rier and Kollidon VA64, as a hydrophilic polymer was successfully
applied to improve dissolution rate of CBZ. It was demonstrated
that CBZ dissolution rate from the prepared solid dispersions is
sensitive on the changing of the proportions of all ingredients,
which highly supports using of in silico modelling techniques, such
as experimental design in the systematic development of these
systems. Comprehensive solid state characterisation of ternary
solid dispersions showed polymorphic transition from stable mon-
oclinic form III of carbamazepine to metastable form I, which was
not observed for binary solid dispersions that contain only CBZ and
Neusilin UFL2. Although conversion into metastable polymorph
of CBZ resulted in significant improvement of its dissolution rate,
particular attention should be paid in ensuring long-term stability
of these systems and avoiding reconversion into initial stable poly-
morph. This issue will be subject of further research.
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